News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Navidea Biopharmaceuticals Announces Fourth Quarter and Full-Year 2012 Results
March 7, 2013
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB), a biopharmaceutical company focused on precision diagnostic radiopharmaceuticals, today announced consolidated results for the fourth quarter of 2012 and for the year ended December 31, 2012.
Twitter
LinkedIn
Facebook
Email
Print
Earnings
MORE ON THIS TOPIC
Special edition
Deep Dive: Chinese Biotech Innovation Can’t Be Stopped
October 27, 2025
·
3 min read
·
Annalee Armstrong
Rare diseases
Dyne Primed for Suitors Amid Novartis’ $12B Avidity Acquisition
October 27, 2025
·
2 min read
·
Tristan Manalac
M&A
Novartis To ‘Bolster’ Neuromuscular Pipeline With $12B Avidity Acquisition
October 26, 2025
·
2 min read
·
Heather McKenzie
Deals
Lilly Dives Deeper Into Gene Therapy With up to $262M Adverum Buy
October 24, 2025
·
2 min read
·
Heather McKenzie
